Prognostication in Pulmonary Arterial Hypertension - 01/07/12
Corresponding author. Pulmonary Hypertension Center, University of Chicago Medicine, 5841 South, Maryland Avenue, Room L-08, MC 5403, Chicago, IL 60637.Résumé |
Despite the advances in diagnostic and treatment strategies, and contemporary survival estimates suggesting improved outcomes, the prognosis of patients with pulmonary arterial hypertension (PAH) remains poor. To date, there is no consensus on which prognostic variables or risk prediction strategies best predict survival, at baseline and at different time points in the disease course. Even less clear is whether current prognostic variables accurately reflect disease severity and can sufficiently guide therapeutic decisions. This article reviews the most common factors used for prognostication in PAH, emphasizing that proper strategies for identifying patients at greatest risk are paramount.
Le texte complet de cet article est disponible en PDF.Keywords : Pulmonary arterial hypertension, Survival, Prognostic factors, Risk prediction
Plan
| Disclosures: Richa Agarwal has no disclosures. Actelion, Gilead, Medtronic, Novartis, and United Therapeutics have provided funding to the University of Chicago to support Dr Gomberg-Maitland’s conduct of clinical trials. She has served as a consultant/participant on data safety monitoring board/steering committee for clinical trials for Actelion, Gilead, Medtronic, and Pfizer. |
Vol 8 - N° 3
P. 373-383 - juillet 2012 Retour au numéro
Article précédent
- Imaging in the Evaluation of Pulmonary Artery Hemodynamics and Right Ventricular Structure and Function
- Asghar A. Fakhri, Rachel A. Hughes-Doichev, Robert W.W. Biederman, Srinivas Murali
- Pharmacotherapy for Pulmonary Arterial Hypertension
- Gautam V. Ramani, Myung H. Park
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?